Strategic medical plans, their objectives and the initiatives that deliver them. Every initiative must trace to an approved objective.
Active plans
Objectives on track / at risk / off track
| Plan | Product | Scope | Lifecycle stage | Period | Status | Version | Owner | Budget planned vs actual | Review date |
|---|---|---|---|---|---|---|---|---|---|
Nephrada Global Pre-launch Medical Plan FY2026 MP-2026-NPH-G | Nephrada | Global | Pre-launch | FY2026 | Active | v2 | MLDr. Marcus Lindqvist | 57% $2.4M of $4.2M | 15 Oct 2026 |
| Objective | Product | Owner | Status | Progress | Confidence | Initiatives | Plan |
|---|---|---|---|---|---|---|---|
Build understanding of proteinuria reduction as a validated surrogate endpoint among nephrologists… SO-NPH-01 | Nephrada | MLDr. Marcus Lindqvist | On track | 61% | Medium | 1 | Nephrada Global Pre-launch Medical Plan FY2026 |
Generate long-term eGFR slope evidence to support full approval and HTA submissions. SO-NPH-02 | Nephrada | NPDr. Nikolai Petrov | Off track | 22% | Low | 1 | Nephrada Global Pre-launch Medical Plan FY2026 |
Establish patient-advocacy partnerships to inform patient-relevant outcome measures. SO-NPH-03 | Nephrada | SLDr. Sophie Laurent | On track | 50% | Medium | 1 | Nephrada Global Pre-launch Medical Plan FY2026 |
| Initiative | Type | Product | Objective | Owner | Dates | Status | Priority | Progress | Budget vs spend |
|---|---|---|---|---|---|---|---|---|---|
| Medical education program | Nephrada | SO-NPH-01 | ABDr. Anna Becker | 15 Feb 2026 – 15 Dec 2026 | In progress | High | 62% | $164k / $290k | |
| RWE project | Nephrada | SO-NPH-02 | NPDr. Nikolai Petrov | 01 Apr 2026 – 31 Dec 2028 | Blocked | Critical | 18% | $85k / $2.1M | |
| Advisory board | Nephrada | SO-NPH-03 | SLDr. Sophie Laurent | 01 May 2026 – 30 Nov 2026 | In progress | Medium | 50% | $41k / $85k |